Categories: News

Senseonics Holdings, Inc. Schedules Second Quarter 2023 Earnings Release and Conference Call for August 10, 2023 at 4:30 p.m. Eastern Time

GERMANTOWN, Md.–(BUSINESS WIRE)–Senseonics Holdings, Inc. (NYSE-American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced that it plans to release its second quarter 2023 financial results after market close on Thursday, August 10, 2023.


Management will hold a conference call to review the Company’s second quarter 2023 performance starting at 4:30 p.m. (Eastern Time) on the same day. The conference call will be concurrently webcast. The link to the webcast will be available on Senseonics Holdings, Inc. website at www.senseonics.com by navigating to “Investor Relations,” and then “Events & Publications,” and will be archived there for future reference. To listen to the conference call, please dial 1-888-317-6003 (US/Canada) or 1-412-317-6061 (International), passcode 2402364, approximately ten to five minutes prior to start time.

About Senseonics

Senseonics Holdings, Inc. (“Senseonics”) is a medical technology company focused on the development and manufacturing of glucose monitoring products designed to transform lives in the global diabetes community with differentiated, long-term implantable glucose management technology. Senseonics’ CGM systems, Eversense®, Eversense® XL and Eversense® E3 include a small sensor inserted completely under the skin that communicates with a smart transmitter worn over the sensor. The glucose data are automatically sent every 5 minutes to a mobile app on the user’s smartphone.

Contacts

INVESTOR CONTACT
Philip Taylor

Gilmartin Group

415-937-5406

investors@senseonics.com

Staff

Recent Posts

cbdMD Announces Company’s CEO Joins the Board of Directors

Charlotte, North Carolina--(Newsfile Corp. - December 23, 2024) - cbdMD, Inc. (NYSE American: YCBD) (NYSE…

5 hours ago

Interactive Strength Inc. (Nasdaq: TRNR) Issues Year-End Update, Looks Ahead to 2025

AUSTIN, TEXAS / ACCESSWIRE / December 23, 2024 / Interactive Strength Inc. (Nasdaq:TRNR) ("TRNR" or…

6 hours ago

Quest Diagnostics Upholds Strong Governance and Ethics With Robust Oversight, ESG Integration, and Comprehensive Risk Management

Originally published in Quest Diagnostics' 2023 Corporate Responsibility ReportNORTHAMPTON, MA / ACCESSWIRE / December 23,…

6 hours ago

Phio Pharmaceuticals Announces Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Marlborough, Massachusetts--(Newsfile Corp. - December 23, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical-stage…

7 hours ago

ILiAD Biotechnologies Announces the Passing of Chief Operating Officer Ken Solovay

WESTON, Fla.--(BUSINESS WIRE)--ILiAD Biotechnologies, LLC (ILiAD), a clinical stage biotech company developing the world’s most…

9 hours ago

ILiAD Biotechnologies Announces the Passing of Chief Operating Officer Ken Solovay

WESTON, Fla.--(BUSINESS WIRE)--ILiAD Biotechnologies, LLC (ILiAD), a clinical stage biotech company developing the world’s most…

9 hours ago